ligelizumab

From Aaushi
Jump to navigation Jump to search

Indications

* large beneficial effect in antihistamine-refractory chronic spontaneous urticaria[3]

Dosage

  • 72, 120 or 240 mg SQ every 4 weeks[3]

Mechanism of action

More general terms

References

  1. Maurer M, Gimenez-Arnau, Sussman G et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med 2019 Oct 3; 381:1321 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31577874 https://www.nejm.org/doi/10.1056/NEJMoa1900408
  2. Bowser AD New Hope for Chronic Spontaneous Urticaria? Ligelizumab and other drugs could offer relief for patients with 'the devil's itch'. MedPage Today. AAD Reading Room 11.05.2019 https://www.medpagetoday.com/reading-room/aad/general-dermatology/83142
  3. 3.0 3.1 3.2 Nochaiwong S, Chuamanochan M, Ruengorn C et al Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria. A Systematic Review and Network Meta-analysis. JAMA Dermatol. Published online August 25, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34431983 https://jamanetwork.com/journals/jamadermatology/fullarticle/2783033